Skip to main content

Advertisement

SpringerLink
Log in

Surveillance, Epidemiology, and End Results program underestimates breast cancer-specific mortality after ductal carcinoma in situ diagnosis

  • Letter to the Editor
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Early Breast Cancer Trialists’ Collaborative Group et al (2010) Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr 2010(41):162–177

    Article  Google Scholar 

  2. Barrio AV, Van Zee KJ (2017) Controversies in the treatment of ductal carcinoma in situ. Annu Rev Med 68:197–211

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Narod SA et al (2015) Breast cancer mortality after a diagnosis of ductal carcinoma in situ. JAMA Oncol 1(7):888–896

    Article  PubMed  Google Scholar 

  4. Narod SA, Ahmed H, Sopik V (2017) Wherein the authors attempt to minimize the confusion generated by their study ’’Breast cancer mortality after a diagnosis of ductal carcinoma in situ’’ by several commentators who disagree with them and a few who don't: a qualitative study. Curr Oncol 24(4):e255–e260

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Narod SA, Sopik V (2018) Is invasion a necessary step for metastases in breast cancer? Breast Cancer Res Treat 169(1):9–23

    Article  PubMed  PubMed Central  Google Scholar 

  6. National Cancer Institute. Question: 20110111. 03–06–2020; Available from: https://seer.cancer.gov/seerinquiry/index.php?page=view&id=20110111&type=q.

Download references

Funding

Neither of the authors received external funding for this study. The contributor Olivier Harismendy is supported by awards from the National Cancer Institute (U01CA196406 and P30CA023100).

Author information

Authors and Affiliations

  1. Division of Breast Surgery and the Comprehensive Breast Health Center, University of California San Diego, 3855 Health Sciences Dr, La Jolla, Mailbox 0819, San Diego, CA, 92037, USA

    Thomas J. O’Keefe & Anne M. Wallace

Authors
  1. Thomas J. O’Keefe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anne M. Wallace
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

We thank Sarah L Blair, MD and Ava Hosseini, MD, both of the Division of Breast Surgery and the Comprehensive Breast Health Center, and Olivier Harismendy, PhD, of the Moores Cancer Center Department of Bioinformatics for their contributions to this work.

Corresponding author

Correspondence to Thomas J. O’Keefe.

Ethics declarations

Conflict of interest

We have no relevant conflicts of interest to disclose.

Ethical approval

This article does not contain any studies with human participants performed by any of the authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

O’Keefe, T.J., Wallace, A.M. Surveillance, Epidemiology, and End Results program underestimates breast cancer-specific mortality after ductal carcinoma in situ diagnosis. Breast Cancer Res Treat 182, 761–762 (2020). https://doi.org/10.1007/s10549-020-05733-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-020-05733-z

Search

Navigation